… in patients with non–small-cell lung cancer (… gefitinib. One of these mutations, L858R (Leu→Arg),
is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment…

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… in ∼50% of patients relapsing after an initial … of a lung cancer patient initially responsive to
gefitinib [13]. Two recent studies revealed amplification of MET oncogene in ∼20% of patients …

… study, gefitinib induced autophagy in lung cancer A549 cells while … cells rarely exhibited
autophagy or apoptosis and cell proliferation was not suppressed in response to gefitinib therapy…

… lung cancer samples from US patients who responded to gefitinib therapy and in a lung
adenocarcinoma cell … inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. …

… are useful approaches to identifying the mechanism of gefitinib resistance … gefitinib, we
established a human non-small cell lung carcinoma subline (PC-9/ZD) that is resistant to gefitinib. …

… We randomly assigned 230 patients with metastatic, non–small-cell lung cancer and EGFR
mutations who had not previously received chemotherapy to receive gefitinib or carboplatin–…

… to identify which patients may respond to gefitinib therapy, we evaluated … patients with
advanced NSCLC before starting gefitinib therapy and evaluated their response to gefitinib therapy…

… disease, which is relatively common in Japanese patients. … gefitinib treatment in NSCLC
patients with EGFR mutations, as adjuvant treatment is considered the earliest treatment of …

… Patients were classified as nonsmokers (never smoker), former smokers (quit smoking > 6 …
gefitinib therapy), or current smokers (quit smoking < 6 months before starting gefitinib therapy …